We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against the other best biotech stocks to buy under $20.
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support. The aging population and rising healthcare needs are creating a strong market for new therapies, while breakthroughs in areas like gene editing, sequencing, personalized medicine, and AI are enabling the development of novel approaches. Between 2019 and 2021, venture capital firms invested over $52 billion in therapeutic-focused biotech companies worldwide. Of this total, two-thirds was allocated to start-ups with platform technologies.
By addressing critical unmet medical needs, biotech companies are transforming healthcare with groundbreaking therapies. A key development in this space is the launch of the National Bioeconomy Board as part of Biden’s Investing in America agenda. It aims to harness the potential of biotechnology for the U.S. economy.
In addition to this, the National Security Commission on Emerging Biotechnology is developing policy recommendations to streamline the regulatory process for biotechnology products. By lowering barriers to entry, more researchers can leverage biotechnology for agricultural applications, supporting U.S. farmers and improving food security. These efforts are expected to create new market opportunities.
Also Read: 10 Largest Biotech Hedge Funds and Their Top Stock Picks
Market Growth Forecast
The biotechnology industry has seen an increase in mergers and acquisitions activity, along with expectations of declining interest rates which have contributed to a strong start in 2024. As a result, projections indicate the global biotechnology market could reach an impressive $5.7 trillion by 2033, growing at a compound annual growth rate (CAGR) of nearly 14% from 2024 to 2033. Even the agricultural biotechnology market is forecasted to grow at a 7.9% CAGR, reaching a market value of $232 billion by 2032.
However, despite the market’s potential, significant risks remain when investing in biotech companies. A failure to meet clinical trial endpoints or secure sufficient funding before a product launch can lead to bankruptcy. The risk of failure is especially high in the biotech sector, where drug development typically takes over a decade and has an estimated failure rate of around 90%.
Hence, biotech stocks are often considered “high-risk, high-reward” investments due to their upside potential coupled with significant risks. If you’re interested in exploring this sector, a good strategy might be to focus on promising but cheap biotech stocks.
Our Methodology
To identify the top biotech stocks to buy under $20, we analyzed the biotech companies that were most popular among hedge funds as of Q2 2024 and traded under $20. Analysts are optimistic about these companies due to their potential to deliver strong returns for investors. Drawing from Insider Monkey’s comprehensive database of over 900 hedge funds, we ranked the best biotech stocks under $20 in ascending order based on their popularity among hedge funds as of Q2, 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule.
Travere Therapeutics, Inc. (NASDAQ:TVTX)
Number of Hedge Fund Holders: 34
Price: $14.97
Starting out in 2008, the San Diego, California-based firm, Travere Therapeutics, Inc. (NASDAQ:TVTX) is dedicated to improving the lives of patients with rare diseases. It is focused on developing treatments for rare kidney and metabolic diseases. Travere Therapeutics, Inc.’s (NASDAQ:TVTX) lead drug candidate, sparsentan, has received FDA approval for slowing kidney function decline, which is a major achievement for the company.
In the second quarter, Travere Therapeutics, Inc.’s (NASDAQ:TVTX) operational performance remained strong, driven by a significant rise in net product sales and a reduction in operating cash usage. Net product sales for Q2 2024 reached $52.2 million, as opposed to $29.5 million during the same period in 2023. This 77% increase is largely due to the growth in net product sales from the ongoing US launch of FILSPARI and the treatment of IgA nephropathy.
Travere Therapeutics, Inc. (NASDAQ:TVTX) has also increased R&D investments, which shows a strong commitment to innovation and future profitability. Analysts are bullish on the stock, giving an average ‘Moderate Buy’ rating and a 1-year price target of $17.91. The stock is held by 34 hedge funds tracked by Insider Monkey, as of Q2 2024, making it one of the best biotech stocks to buy now.
Overall, TVTX ranks 2nd among the 10 best biotech stocks to buy under $20. While we acknowledge the potential of TVTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TVTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.